Skip to main content

Global Interventional Oncology Market: The Role of Global Collaboration in Achieving 11% CAGR by 2030

 


The interventional oncology market is projected to grow at a CAGR of 11% over the forecast period. Major factors driving growth include the increasing prevalence of cancer globally, the rising adoption of minimally invasive procedures, advancements in imaging technologies, and an aging population susceptible to oncology-related diseases. Additionally, growing awareness of interventional oncology among healthcare providers further accelerates its adoption. However, the market faces restraints such as high procedural costs, limited skilled professionals, and stringent regulatory approvals for innovative technologies.

Interventional oncology is a rapidly evolving subspecialty of interventional radiology that focuses on diagnosing and treating cancer using minimally invasive procedures. It employs advanced imaging techniques such as ultrasound, CT scans, and MRI to guide targeted therapies directly to tumors. Procedures include thermal ablation (radiofrequency and microwave ablation), transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT). These techniques provide precise treatment while minimizing damage to healthy tissues, resulting in reduced recovery time and fewer complications compared to traditional cancer treatments.

Download a free sample report for in-depth market insights

https://meditechinsights.com/global-interventional-oncology-market/request-sample/

Rising Cancer Incidence and Shifting Focus Toward Patient-Centric Care

The growing incidence of cancer worldwide is a significant factor driving the interventional oncology market. According to the International Agency for Research on Cancer (IARC), there were close to 20 million new cases of cancer in 2022, alongside 9.7 million deaths from cancer. With millions of new cancer cases diagnosed annually, there is an urgent demand for advanced treatment options that provide effective outcomes while minimizing patient burden. Interventional oncology fulfils this need by offering image-guided, minimally invasive procedures such as thermal ablation and embolization therapies. These approaches reduce surgical trauma, shorten hospital stays, and improve post-treatment quality of life, especially for patients who are elderly or have underlying health conditions. Moreover, healthcare systems are increasingly prioritizing patient-centric care by adopting innovative methods that balance clinical efficacy with cost efficiency. As awareness of these benefits grows among oncologists and patients, the adoption of interventional oncology continues to expand globally.

AI-Driven Precision in Interventional Oncology

The integration of artificial intelligence (AI) into interventional oncology represents a transformative advancement in the field. AI enhances procedural accuracy by improving tumour visualization, segmentation, and monitoring in imaging modalities like CT, MRI, and ultrasound. This allows clinicians to precisely plan and execute minimally invasive treatments, optimizing outcomes for patients. AI-powered tools also assist in predicting treatment responses and customizing therapies based on patient-specific factors, enabling a personalized approach to cancer care. Additionally, automated analysis of imaging data reduces the time required for diagnosis and decision-making, streamlining workflows and improving efficiency for healthcare providers. As these AI applications become more sophisticated, they contribute to higher success rates, fewer complications, and greater accessibility to advanced interventional oncology techniques, positioning AI as a cornerstone of future innovation in cancer treatment.

Competitive Landscape Analysis

The global interventional oncology market is marked by the presence of established and emerging market players such as Medtronic plc; Boston Scientific Corporation; Johnson & Johnson; Cook Medical; Becton, Dickinson and Company; AngioDynamics Inc.; Stryker Corporation; B. Braun Melsungen AG; Terumo Corporation; Siemens Healthineers; and GE Healthcare among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Unlock key data with a sample report for competitive analysis:

https://meditechinsights.com/global-interventional-oncology-market/request-sample/

Market Segmentation

This report by Medi-Tech Insights provides the size of the global interventional oncology market at the regional- and country-level from 2023 to 2030. The report further segments the market based on technique, procedure, application and end-user.

  • Market Size & Forecast (2023-2030), By Technique, USD Million
    • Ablation Therapies
      • Radiofrequency Ablation (RFA)
      • Microwave Ablation (MWA)
      • Cryoablation
      • Laser Ablation
      • Irreversible Electroporation (IRE)
    • Embolization Therapies
      • Transarterial Chemoembolization (TACE)
      • Transarterial Radioembolization (TARE)
    • Biopsy Techniques
      • Core Needle Biopsy
      • Fine Needle Aspiration (FNA)
    • Targeted Therapy Delivery Systems
      • Drug-eluting Beads
      • Radioembolization
      • Drug-eluting Stents
      • Injectable Hydrogels and Nanoparticles
      • Other Targeted Therapy Systems
    • Image-Guided Procedures
      • Ultrasound Guidance
      • CT Scan Guidance
      • MRI Guidance
      • Fluoroscopy Guidance
  • Market Size & Forecast (2023-2030), By Procedure, USD Million
    • Tumor Ablation
    • Tumor Biopsy
    • Vascular Interventions
    • Palliative Care
  • Market Size & Forecast (2023-2030), By Application, USD Million
    • Liver Cancer
    • Lung Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Breast Cancer
    • Other Cancer
  • Market Size & Forecast (2023-2030), By End-user, USD Million
    • Hospitals
    • Specialty Centers
    • Others
  • Market Size & Forecast (2023-2030), By Region, USD Million
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Rest of Asia Pacific
    • Latin America
    • Middle East & Africa

 

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Structural Heart Devices Market growth 9% CAGR with favorable reimbursement scenarios 2030

  The global structural heart devices market is set to witness a CAGR of ~9% in the next 5 years.  The rising geriatric population & corresponding rise in the prevalence of heart disease, technological advancements in structural heart devices, regulatory approval for expanded indications for several transcatheter heart valves, and increasing awareness and favorable reimbursements for these procedures in key markets are some of the pivotal factors driving the growth of the structural heart devices market. However, high device costs, complex procedures, and stringent regulatory hurdles continue to restrain market uptake.  Structural heart disease occurs when something is wrong with one’s heart valves, walls, chambers or muscles. It exists from birth or develops as one age. It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease. Heart valve devices, occluders & delivery systems, annuloplasty rings, heart access systems, cl...
Post a Comment
Read more